Aviso: Este sitio agrega datos públicos oficiales de la FDA, ClinicalTrials.gov, PubMed y SEC EDGAR solo como referencia general. No constituye asesoramiento médico, diagnóstico, recomendaciones de tratamiento ni asesoramiento de inversión.

PubMed

Effect of the FDA Safety and Innovation Act on racial and gender diversity in neurosurgical device trials.

PMID: 34171831 ·

N, e, h, a, , S, i, d, d, i, q, u, i, ;, , R, y, a, n, , G, , C, h, i, u, ;, , R, a, v, i, , S, , N, u, n, n, a, ;, , G, e, o, r, g, i, a, , G, l, a, s, t, r, i, s, ;, , A, n, k, i, t, , I, , M, e, h, t, a

RevistaJournal of neurosurgery
Año
PMID34171831

Resumen

The US FDA uses evidence from clinical trials in its determination of safety and utility. However, these trials have often suffered from limited external validity and generalizability due to unrepresentative study populations with respect to clinical patient demographics. Section 907 of the FDA Safety and Innovation Act (FDASIA) of 2012 attempted to address this issue by mandating the reporting of certain study demographics in new device applications. However, no study has been performed on its

Fuente oficial

Ver en PubMed →

Datos obtenidos de PubMed / NCBI. Para consultar el texto completo y la información más reciente, remítase siempre al registro oficial.

↑